Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.48 |
| ▸ | WNT1 | P04628 | 5/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKACG | P22612 | 1/20 | 0.47 |
| ▸ | PRKACB | P22694 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | CLK3 | P49761 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201534 | 0.81 | DYRK1A (0.57) | ROCK2DYRK1AWNT1GSK3B | |
| SCHEMBL27201421 | 0.80 | DYRK1A (0.50) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201405 | 0.79 | DYRK1A (0.67) | DYRK1AWNT1CLK2CLK3GSK3B | |
| SCHEMBL27201264 | 0.76 | GSK3B (0.56) | DYRK1AGSK3B | |
| SCHEMBL27201483 | 0.75 | DYRK1A (0.59) | DYRK1AGSK3BCDK2 | |
| SCHEMBL30885311 | 0.75 | DYRK1A (0.59) | DYRK1AGSK3BCDK2 | |
| SCHEMBL27201655 | 0.74 | GSK3B (0.69) | DYRK1AGSK3B | |
| SCHEMBL1647671 | 0.74 | ROCK2 (0.71) | ROCK2SMN1; SMN2PRKACAPRKACGPRKACB | |
| SCHEMBL12779302 | 0.72 | ROCK2 (0.78) | ROCK2SMN1; SMN2PRKACAPRKACGPRKACB | |
| SCHEMBL27201475 | 0.71 | DYRK1A (0.71) | DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | ROCK2 3587/4885SMN1; SMN2 1597/4885DYRK1A 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.